000 04212nlm1a2200625 4500
001 669249
005 20231030042216.0
035 _a(RuTPU)RU\TPU\network\40489
035 _aRU\TPU\network\40172
090 _a669249
100 _a20230310a2023 k y0engy50 ba
101 0 _aeng
102 _aCH
135 _adrcn ---uucaa
181 0 _ai
182 0 _ab
200 1 _aCardioprotective Effects of a Selective c-Jun N-terminal Kinase Inhibitor in a Rat Model of Myocardial Infarction
_fM. B. Plotnikov, G. A. Chernysheva, V. I. Smol'yakova [et al.]
203 _aText
_celectronic
300 _aTitle screen
320 _a[References: 92 tit.]
330 _aActivation of c-Jun N-terminal kinases (JNKs) is involved in myocardial injury, left ventricular remodeling (LV), and heart failure (HF) after myocardial infarction (MI). The aim of this research was to evaluate the effects of a selective JNK inhibitor, 11H-indeno [1,2-b]quinoxalin-11-one oxime (IQ-1), on myocardial injury and acute myocardial ischemia/reperfusion (I/R) in adult male Wistar rats. Intraperitoneal administration of IQ-1 (25 mg/kg daily for 5 days) resulted in a significant decrease in myocardial infarct size on day 5 after MI. On day 60 after MI, a significant (2.6-fold) decrease in LV scar size, a 2.2-fold decrease in the size of the LV cavity, a 2.9-fold decrease in the area of mature connective tissue, and a 1.7-fold decrease in connective tissue in the interventricular septum were observed compared with the control group. The improved contractile function of the heart resulted in a significant (33%) increase in stroke size, a 40% increase in cardiac output, a 12% increase in LV systolic pressure, a 28% increase in the LV maximum rate of pressure rise, a 45% increase in the LV maximum rate of pressure drop, a 29% increase in the contractility index, a 14% increase in aortic pressure, a 2.7-fold decrease in LV end-diastolic pressure, and a 4.2-fold decrease in LV minimum pressure. We conclude that IQ-1 has cardioprotective activity and reduces the severity of HF after MI.
461 _tBiomedicines
463 _tVol. 11, iss. 3
_v[714, 15 p.]
_d2023
610 1 _aэлектронный ресурс
610 1 _aтруды учёных ТПУ
610 1 _acardioprotective activity
610 1 _ac-Jun N-terminal kinase inhibitor
610 1 _a11H-indeno[1,2-b]quinoxalin-11-one oxime
610 1 _aheart failure
610 1 _ainfarct size
610 1 _amyocardial infarction
610 1 _aischemia/reperfusion
610 1 _aсердечная недостаточность
610 1 _aинфаркт миокарда
610 1 _aишемия
610 1 _aреперфузия
701 1 _aPlotnikov
_bM. B.
_gMark
701 1 _aChernysheva
_bG. A.
_gGalina
701 1 _aSmol'yakova
_bV. I.
_gVera
701 1 _aAliev
_bO. I.
_gOleg
701 1 _aFomina
_bT. I.
_gTatyana
701 1 _aSandrikina
_bL. A.
_gLyubov
701 1 _aSukhodolo
_bI. V.
_gIrina
701 1 _aIvanova
_bV. V.
_gVera
701 1 _aOsipenko
_bA. N.
_gAnton
701 1 _aAnfinogenova
_bN. D.
_gNina
701 1 _aKhlebnikov
_bA. I.
_cChemist
_cProfessor of Tomsk Polytechnic University
_f1963-
_gAndrey Ivanovich
_2stltpush
_3(RuTPU)RU\TPU\pers\33927
701 1 _aAtochin
_bD. N.
_cneuroscientist
_cThe Head of the Laboratory of Tomsk Polytechnic University
_f1960-
_gDmitry Nikolaevich
_2stltpush
_3(RuTPU)RU\TPU\pers\37514
701 1 _aSchepetkin (Shchepyotkin)
_bI. A.
_cdoctor-biophysicist
_cleading researcher of Tomsk Polytechnic University, candidate of medical science
_f1962-
_gIgor Aleksandrovich
_2stltpush
_3(RuTPU)RU\TPU\pers\37358
701 1 _aQuinn
_bM. T.
_gMark
712 0 2 _aНациональный исследовательский Томский политехнический университет
_bИнженерная школа новых производственных технологий
_bНаучно-образовательный центр Н. М. Кижнера
_h7872
_2stltpush
_3(RuTPU)RU\TPU\col\23556
801 2 _aRU
_b63413507
_c20230329
_gRCR
856 4 _uhttp://earchive.tpu.ru/handle/11683/74886
856 4 _uhttps://doi.org/10.3390/biomedicines11030714
942 _cCF